Mary Minkin
Obstetrics & Gynecology · New Haven, CTNPI 1760445290
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Pfizer at 28.6% of the total. Among obstetrics & gynecology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $1081.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$82K
- Therapeuticsmd, Inc.$76K
- Astellas Pharma US Inc$58K
- Bayer$36K
- Mayne Pharma Commercial LLC$21K
- Duchesnay USA Incorporated$6K
- plus $7K from 8 others
What the payments were for
- Consulting fees$108,83538%
- Speaking & faculty fees$154,87354%
- Travel & lodging$15,4685%
- Food & beverage$6,0642%
- Education$2600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 45 | $81,612 |
| Therapeuticsmd, Inc. | 82 | $76,038 |
| Astellas Pharma US Inc | 64 | $57,928 |
| Bayer | 24 | $35,975 |
| Mayne Pharma Commercial LLC | 15 | $20,976 |
| Duchesnay USA Incorporated | 10 | $6,227 |
| AMAG Pharmaceuticals, Inc. | 8 | $3,313 |
| Myovant Sciences Inc. | 2 | $2,905 |
| Sumitomo Pharma America, Inc. | 2 | $224 |
| Millicent US Inc | 4 | $147 |
| AbbVie(2 entities) | 5 | $88 |
| Astellas Pharma Global Development | 1 | $30 |
| Urovant Sciences Inc | 1 | $19 |
| Coopersurgical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$285,500 in reported general payments places this provider in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 442 | $31,775 |
| PremarinEstrogens, Conjugated | 44 | $21,345 |
| YuvafemEstradiol | 115 | $16,966 |
| VeozahFezolinetant | 20 | $15,110 |
| MyrbetriqMirabegron | 17 | $14,863 |
| GemtesaVibegron | 12 | $14,795 |
| OsphenaOspemifene | 14 | $9,915 |
| DuaveeEstrogens,conj/Bazedoxifene | 19 | $9,772 |
| EstringEstradiol | 18 | $9,472 |
| EstraceEstradiol | 11 | $7,498 |
| VagifemEstradiol | 15 | $7,082 |
| Estradiol (Twice Weekly)Estradiol | 64 | $7,003 |
| ImvexxyEstradiol | 12 | $6,842 |
| Estradiol (Once Weekly)Estradiol | 65 | $5,346 |
| ProgesteroneProgesterone, Micronized | 113 | $4,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Duavee, Estring | $81,612 | $40,58981 claims |
| Astellas Pharma US IncVeozah, Myrbetriq | $57,928 | $29,97237 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $224 | $14,79512 claims |
| Duchesnay USA IncorporatedOsphena | $6,227 | $9,91514 claims |
| Therapeuticsmd, Inc.Imvexxy | $76,038 | $6,84212 claims |
| AbbVieSynthroid | $88 | $1,42511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.
Other obstetrics & gynecology in New Haven
- Alessandro SantinNew Haven$98K
- Randall KaumpNew Haven$16K
- Elena RatnerNew Haven$8K
- Sangini ShethNew Haven$5K
- Catherine SalvaNew Haven$5K
- Tessa MaddenNew Haven$4K
- Emre SeliNew Haven$4K
- Frederick RauHartford$89K
- Peter AuerbachGroton$41K
- Shieva GhofranyStamford$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.